HBSAG Decline and Clearance during Long-Term Tenofovir Therapy in Patients Co-Infected with Hepatitis B and Human Immunodeficiency Virus
The Journal of Infectious Diseases, 07/17/2012
Zoutendijk R et al. – Tenofovir (TDF) for HIV/HBV patients up to 6 years leads to significant HBsAg decline in the HBeAg–positive population. Early HBsAg kinetics were predictive for HBsAg seroclearance and correlated with increase of CD4 cell count, underlining the importance of immune restoration in HBV clearance.